Eric Vilain | |
---|---|
Born | 1966 |
Alma mater | |
Known for | Genetics of Disorders/Differences of Sex Development, biology of gender identity, biology of sexual orientation |
Scientific career | |
Fields | Genetics, Endocrinology, Sexual Development |
Institutions | University of California, Los Angeles – David Geffen School of Medicine Children’s National Medical Center George Washington University School of Medicine and Health Sciences ContentsUniversity of California, Irvine |
Doctoral advisor | Marc Fellous |
Eric Vilain is a physician-scientist and professor in the fields of Differences of Sex Development (DSDs) and precision medicine. He is the Associate Vice Chancellor for Scientific Affairs at the University of California, Irvine Health Affairs and also the director of the UCI Institute for Clinical and Translational Science [1] . He previously was the director of the Center for Genetic Medicine Research at Children's National Medical Center and the chair of the Department of Genomics and Precision Medicine at the George Washington University School of Medicine & Health Sciences in Washington, D.C. [2] [3] [4] Vilain is a fellow of the American College of Medical Genetics, serves on the International Olympic Committee's Medical Commission, and sits on the Board of Scientific Counselors for the National Institute of Child Health and Human Development (NICHD).
Vilain is known for his research on the molecular mechanisms of DSDs, using DNA sequencing and animal models to discover the biological bases of sex differentiation. In addition to DSDs, Vilain has also published a large body of research on sex differences in the brain, the biology of sexual orientation, and gender identity. Vilain is described as "one of the world's foremost experts on the genetic determinants of DSDs" in the journal Nature. [5]
Vilain was born in 1966, in Paris, France. He attended the Faculté de Médecine Necker Enfants Malades in 1983, and obtained his MD in 1989. His first rotation as a medical student was in the referral center for the intersex newborns, which, he notes, was what first drove him to research DSDs. [6] In 1990, Vilain attended the Pasteur Institute at the Université Pierre et Marie Curie and obtained his PhD in genetics in 1994. Vilain then moved to Los Angeles, California in 1995 [7] to complete his residency and to train as a postdoctoral research fellow of Medical Genetics at the University of California, Los Angeles. In 1998, Vilain became a professor of Human Genetics and Pediatrics at the UCLA School of Medicine, and served as the Chief of Medical Genetics at the Department of Pediatrics and the Department of Urology until 2017. Vilain left UCLA in 2017 to become the director of the Center for Genetic Medicine Research at Children's National Medical Center and the chair of the Department of Genomics and Precision Medicine at the George Washington University School of Medicine and Health Sciences. In 2022 Vilain became the Associate Vice Chancellor for Scientific Affairs at University of California, Irvine.
Vilain is an expert on the Disorders of Sex Development and has published widely on the genetic pathways and molecular mechanisms underlying human sexual development. [7] His early research focused on the gene SRY and its role in the formation of the testes, as well as how certain mutations could explain diseases such as gonadal dysgenesis. [8] During his time at UCLA, he created mouse models to observe the effects of mutations on genes linked to sexual development. In 1999, Vilain was the first geneticist to describe IMAGe syndrome, a rare and severe congenital disease, and in 2012, identified its causative mutations. [9] [10]
In 2005, he was one of the pediatricians present at the International Consensus Conference on Intersex in Chicago, to advocate for the term "disorders of sex development." He also worked with intersex advocate Bo Laurent to remove the term "hermaphrodite" from the medical vocabulary. In August 2006, Vilain, along with other members of pediatric societies signed the Consensus statement on management of intersex disorders, which stated that "terms such as intersex, pseudohermaphroditism, hermaphroditism, sex reversal, and gender based diagnostic labels are particularly controversial." [11] Vilain would write in a 2007 article for Nature Genetics titled "We Used to Call Them Hermaphrodites," that terms such as "intersex" and "hermaphrodite" should be abandoned, due to their connotations. Vilain is currently one of the principal investigators of the Differences/Disorders of Sex Development Translational Research Network (DSD-TRN), a large research network of 10 different medical sites. Vilain and his collaborators started the DSD-TRN in 2012 as a registry to assist in the care of patients with DSDs. As the Chief of Medical Genetics at UCLA, Vilain helped standardize the genetic and phenotypic reporting of DSDs to assist clinicians in interpretation and diagnosis. [12]
In 2011, Vilain was one of the members of the International Olympic Committee Medical Commission and helped revise the policies on female athletes with DSDs such as androgen insensitivity syndrome (AIS), spurred by the case of South African runner Caster Semenya in 2009. The Medical Commission settled on a testosterone limit of 10 nanomoles per liter of blood to be able to participate in women's events. Vilain has expressed reticence on the policy, citing the inconsistent application of the policy by the International Association of Athletic Federations. [7] [13] In 2019, Vilain served as an expert witness defending Caster Semenya's right to compete as a woman in athletic competitions. [14]
Vilain also researches sex differences in the brain, most notably the biology of gender identity and sexual orientation. Along with other collaborators, Vilain and his team have published papers on the expression of sex-regulating genes effecting the differentiation of brains using mouse models [15] and studied the role the SRY gene plays in regulating adult brain function. [16] In 2006, his team, along with geneticist Dean Hamer, published research studying the linkage of gay males and markers on their mothers' X chromosome. [17] During the 2015 conference of the American Society of Human Genetics, his team presented findings on potential epigenetic differences in identical male twins discordant in sexual orientation. Researchers, however, noted and criticized the small sample size and questioned the statistical power of the study. [18] Since 2014, Vilain has led the joint research unit between the French Centre National de la Recherche Scientifique (CNRS) called EpiDaPo (Epigenetics, Data, Politics), an interdisciplinary research unit which studies the societal effects of genetics, environment, and big data research. [19] Vilain has been conducting global health research in the Democratic Republic of the Congo since 2018, mainly focusing on infectious diseases such as Ebola [20] and genetic factors influencing diet-induced neurodegenerative diseases. [21]
5α-Reductase 2 deficiency (5αR2D) is an autosomal recessive condition caused by a mutation in SRD5A2, a gene encoding the enzyme 5α-reductase type 2 (5αR2). The condition is rare, affects only genetic males, and has a broad spectrum.
Sexual differentiation is the process of development of the sex differences between males and females from an undifferentiated zygote. Sex determination is often distinct from sex differentiation; sex determination is the designation for the development stage towards either male or female, while sex differentiation is the pathway towards the development of the phenotype.
Intersex medical interventions, also known as intersex genital mutilations (IGM), are surgical, hormonal and other medical interventions performed to modify atypical or ambiguous genitalia and other sex characteristics, primarily for the purposes of making a person's appearance more typical and to reduce the likelihood of future problems. The history of intersex surgery has been characterized by controversy due to reports that surgery can compromise sexual function and sensation, and create lifelong health issues. Timing, evidence, necessity and indications for surgeries in infancy, adolescence or adult age have been controversial, associated with issues of consent.
The history of intersex surgery is intertwined with the development of the specialities of pediatric surgery, pediatric urology, and pediatric endocrinology, with our increasingly refined understanding of sexual differentiation, with the development of political advocacy groups united by a human qualified analysis, and in the last decade by doubts as to efficacy, and controversy over when and even whether some procedures should be performed.
Sex-determining region Y protein (SRY), or testis-determining factor (TDF), is a DNA-binding protein encoded by the SRY gene that is responsible for the initiation of male sex determination in therian mammals. SRY is an intronless sex-determining gene on the Y chromosome. Mutations in this gene lead to a range of disorders of sex development with varying effects on an individual's phenotype and genotype.
XX male syndrome, also known as de la Chapelle syndrome, is a rare congenital intersex condition in which an individual with a 46,XX karyotype has phenotypically male characteristics that can vary among cases. Synonyms include 46,XX testicular difference of sex development, 46,XX sex reversal, nonsyndromic 46,XX testicular DSD, and XX sex reversal.
Ovotesticular syndrome is a term for an intersex condition in which an individual is born with both ovarian and testicular tissue. Commonly, one or both gonads is an ovotestis containing both types of tissue. Although it is similar in some ways to mixed gonadal dysgenesis, the conditions can be distinguished histologically.
Gonadal dysgenesis is classified as any congenital developmental disorder of the reproductive system in humans. It is atypical development of gonads in an embryo,. One type of gonadal dysgenesis is the development of functionless, fibrous tissue, termed streak gonads, instead of reproductive tissue. Streak gonads are a form of aplasia, resulting in hormonal failure that manifests as sexual infantism and infertility, with no initiation of puberty and secondary sex characteristics.
Sex chromosomes are chromosomes that carry the genes that determine the sex of an individual. The human sex chromosomes are a typical pair of mammal allosomes. They differ from autosomes in form, size, and behavior. Whereas autosomes occur in homologous pairs whose members have the same form in a diploid cell, members of an allosome pair may differ from one another.
Sexual differentiation in humans is the process of development of sex differences in humans. It is defined as the development of phenotypic structures consequent to the action of hormones produced following gonadal determination. Sexual differentiation includes development of different genitalia and the internal genital tracts and body hair plays a role in sex identification.
Pseudohermaphroditism is a condition in which an individual has a matching chromosomal and gonadal tissue sex, but mismatching external genitalia.
17β-Hydroxysteroid dehydrogenase III deficiency is a rare autosomal recessive disorder of sexual development condition that is a cause of 46,XY disorder of sex development. The impaired testosterone biosynthesis by 17β-hydroxysteroid dehydrogenase III, presents as atypical genitalia in affected males.
Disorders of sex development (DSDs), also known as differences in sex development, diverse sex development and variations in sex characteristics (VSC), are congenital conditions affecting the reproductive system, in which development of chromosomal, gonadal, or anatomical sex is atypical.
Transcription factor SOX-9 is a protein that in humans is encoded by the SOX9 gene.
Intersex people are individuals born with any of several sex characteristics including chromosome patterns, gonads, or genitals that, according to the Office of the United Nations High Commissioner for Human Rights, "do not fit typical binary notions of male or female bodies".
Morgan Carpenter is a bioethicist, intersex activist and researcher. In 2013, he created an intersex flag, and became president of Intersex Human Rights Australia. He is now a co-executive director. In 2015, he cofounded a project to mark Intersex Awareness Day.
Ieuan Arwel Hughes is a paediatric endocrinologist and an emeritus professor of paediatrics at the University of Cambridge. Hughes is most notable for long-standing research into disorders of sex development (DSD), established one of the largest and most comprehensive databases of cases of DSD including publishing the Consensus on DSD management framework which, barely eight years after its publication, is now already accepted worldwide as the framework for care of patients and families with DSD.
Peter Anthony Koopman is an Australian biologist best known for his role in the discovery and study of the mammalian Y-chromosomal sex-determining gene, Sry.
Sexual anomalies, also known as sexual abnormalities, are a set of clinical conditions due to chromosomal, gonadal and/or genitalia variation. Individuals with congenital (inborn) discrepancy between sex chromosome, gonadal, and their internal and external genitalia are categorised as individuals with a disorder of sex development (DSD). Afterwards, if the family or individual wishes, they can partake in different management and treatment options for their conditions.
Different criteria have been adduced for the definition of intersex, including ambiguous genitalia and atypical genitalia.
{{cite web}}
: Missing or empty |url=
(help)